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Abstract-Currently, the practice of nuclear medicine in modern countries comprises a large number of procedures. 
It is applied to study function of organs/body systems, to visualize, to characterize, and to quantify the functional 
state of lesions and for targeted radionuclide therapy.  This overview presents all kinds of application in nuclear 
medicine services. Instrumentation and radioactive/radiolabeled substances are the basic components for application. 
Biotechnology contributes to the development and production of biomolecules used in radiopharmaceuticals. As a 
diagnostic modality, imaging depicts radioactivity distribution as a function of time. Hybrid imaging provides more 
precise localization and definition of le-sions as well as molecular imaging cross validation. Counting tests study invivo 
organ functions externally or assess analytes in the biologic samples.   Radiopharmaceutical therapy can be applied 
directly into the lesion or targeted systemically. Nanotechnology facilitates targeting and opens the development of 
bimodal techniques. In addition, neutron application contributes to the advancement of nuclear medicine services, such 
as neutron activation analysis, neutron teletherapy and neutron capture therapy. 
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INTRODUCTION
Nuclear medicine (NM) is defined as a 
medical specialty which involves unsealed 
sources of ionizing radiation for diagnosis, 
therapy and study of diseases. Most procedures 
use radiopharmaceuticals, predominately for 
diagnostic activities[1]. Radiopharmaceuticals 
are radiolabeled targeting agents administered 
to the patients. They can be in the form of 
particles, chemicals or biologicals [2].
As a diagnostic modality, NM can 
detect lesions very early, because functional 
(phsiological/biochemical) changes precede 
structure/morphological abnormalities In 
diagnostic workup, it visualizes and characterizes 
lesions, whether they contain viable cells or not, 
as well as what, where and how fast specific 
biological processes are going on. NM is also 
utilized to study organ/body system functions, 
such as performance, perfusion, tube/ tract 
patency, gene expression, etc [3].
The existence of therapeutic modality 
improves and advances the quality of patient 
treatments, particularly, in cancer management. 
NM shares roles with other medical modalities 
[4]. Each modality is not competitive, but 
complementary to the others.
The roles of NM include : identification of 
diseases; prognostication and risk stratification; 
monitoring the course of diseases; adjunctive, 
optional and choice of therapy; follow up 
therapeutic outcomes. NM can be used to 
decide whether the treatment must go on or 
stop, just because, unlike radiologic imaging, 
it can visually differentiate viable lesions from 
necrotic/scar tissues and granulation [5].
PATHOBIOLOGY
A lesion is a site containing functionally/
structurally abnormal cells. Various processes 
may take place such as: neoplasia, inflammation, 
infection, trauma, degeneration, cell dying, 
Indonesian Journal of Physics and Nuclear Applications 
Volume 1, Number 2, June 2016, p. 81-84
ISSN  2549-046X,  © FSM UKSW Publication
82
Indonesian Journal of Physics and Nuclear Application, Vol. 1, No. 2, June 2016
etc.  Each process can be identified by certain 
radiopharmaceuticals, such as: neoplastic 
proliferation by F18-FLT, glycolysis by F18-
FDG, inflammation by Tc99m-fanole-somab, 
brain degeneration by C11-PK11195, apoptosis 
by Tc99m-annexin, infection by Tc99m-
ciprofloxacin and so on [4,2].
RADIOPHARMACEUTICALS
A radiopharmaceutical usually contains a 
radionuclide (label) that is attached to its targeting 
molecule (vector) [4]. Few radionuclides do not 
require vectors, such as: I-131, Tc-99m, P-32, 
Sr-89, Ga-67.  I-131, Tc-99m go to thyroid; 
P-32, Sr-89 respectively to prolifera-ting cells 
and bones; Ga-67 to neoplasma or inflammation. 
Radiopharmaceuticals interact with their 
respective targets at molecular level. Targets 
may be molecules or biochemical pathways. 
Non-biomolecular radiopharmaceuticals can 
be divided in 2 types, namely:    
Inorganic radiopharmaceuticals : P-32, • 
Tc99m-MAA, Tc99m-HAM, Tc99m-
colloid.
Organic radiopharmaceuticals: Tc99m • 
attached to IBI/HMPAO/DTPA/HIDA/
MAG3, I-123-hippuran (see list below, for 
examples).
              
Current and future trend is biomolecular 
radiopharmaceuticals. They interact with 
cellular molecules at selective sites or along 
certain biochemical pathways [1,6].
I n t e r a c t i o n s  o f   b i o m o l e c u l a r 
radiopharmaceuticals (with examples) :
Antigen-antibody* : I131-tositumomab with 1. 
CD20 
Receptor-ligand* : Y90-DOTATOC with 2. 
SSTR
Transporter-ligand* : I123-FPCIT with DAT3. 
Transporter-substrate* : F18-FDG with 4. 
GLUT
Enzyme-substrate*:  F18-FDG with 5. 
hexokinase
Enzyme-ligand*: Ga68-TCTP-1 with matrix 6. 
metalloproteinase-9
The labels determine the use for diagnosis 
or therapy. Gamma or positron emitters are used 
for diagnostic purpose, while particulate, non-
positron emitters are for therapy [4].
INSTRUMENTATION
There are 2 kinds of devices, namely: 
imaging and counting devices [4].
Imaging devices• . These produce pictorial 
outputs (images). Nowadays, all devices 
are digital, such as planar gamma camera, 
SPECT,  and PET.  Hybrid  sys tems 
(SPECT/CT, PET/CT, PET/MRI) precisely 
localize and define lesions with anatomic 
landmarks. 
Counting devices• .  These measure radiation 
intensity, display numerals or histograms. 
For examples: probe system, sample 
counter.   They can be connected to Personal 
Computer.
OUTLINE OF PROCEDURE
As the roles of NM in diagnosis and 
therapy, outline of diagnostic and therapeutic 
procedures are introduced below [4].
Table 1. List of non-biomolecular vectors and targets
VECTORS TARGETS
MAG3
DTPA
HIDA
Colloid
MDP
MAA
MIBI
HMPAO
HAM
Renal tubules
Renal glomerules
Hepatocytes
Reticuloendothelial system
Bone matrix
Lung capillaries
Mitochondria
Brain cells
Serum, liquor compartements
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Diagnostic modality
Application of a radiopharmaceutical is 
followed by observation of its biokinetics and 
functional study of the target organ/body system 
or characterization and assessment of the lesion 
viability and targeted biological process [2]. 
Mode of observation depends on the device 
used.  
Imaging devices•  depict temporal distribution 
of radioavtivity displayed at certain times 
or over preset time period. Image display 
may be 2D (static/dynamic image or whole 
body), 3D (tomogram), 4D (dynamic/
temporal tomogram).
Counting devices• . A probe system is used 
externally to study invivo function of organs/ 
body systems. Sample counters such as 
well-type/liquid scintillation counter are 
used  to measure radiation intensity of 
biologic samples such as blood, serum 
or urine. This sample counting method 
is called radioassay. Invivtro technique 
determines kinds, quantities, con-centrations 
of radioactive materials in the biologic 
samples. It is also called radiobioassay. For 
example : red cell volume determination. 
Invitro technique analyzes non radioactive 
samples by measuring radiation intensity after 
sample treatment with a radioactive reagent. 
For example : radioimmunoassay (RIA).
It is necessary to keep in mind that 
radionuclides for diagnosis and research  are 
ad-ministered in such doses which have no 
observable adverse biological effect.
Therapeutic modality.
This modality utilizes the deleterious 
effect of radiobiologic burden to the lesions. 
Any lesion must receive its therapeutic dose 
without significant adverse reactions [7]. In 
oncology, the doses must be within MTDs 
(maximal tolerable dose) of critical and dose 
limiting organs and the administered activities 
must not exceed MTA (maximal tolerable 
activity) of individual patients.  Hence, accurate 
theranostic dosimetry prior to each therapy must 
be carried out to meet the prerequisite.  It is 
the key of personalized medicine.  Therapeutic 
radiopharmaceuticals may be administered 
directly into or systemically (intravenous, 
orally) to the lesions [8].  Examples are P-32 
ointment applied directly on the skin for keloid 
and I-131 orally for hyperthyroidism.  
NANOTECHNOLOGY
Nanoparticles (NPs) are vehicles used to 
facilitate targeting, especially for penetrating 
biologic barriers such as blood brain barrier. 
Each NP can be loaded with so many molecules. 
Single NP may carry molecules of the same 
target, so targeting effectiveness is enhanced. 
Radiolabeled NPs can be designed to be able 
to penetrate cell and nuclear mem-branes, as 
well as to avoid immune response. Quantum 
dot (QD), superparamagnetic iron oxide NP 
(SPION) can be used for cross-validation of 
bimodal imaging [4,9].  For examples: Cu64-
QD-RGD for PET versus FMT, In 111-SPION-
mesothelin for SPECT versus MRI[10].   Laser 
(NIR) ir-radiation to AuNP produces heat that 
can kill or sensitize tumor to radiation, e.g.: 
Lu177-AuNP-bombesin used for photothermal 
radiation therapy of prostate cancer. Also, 
SPION prodoces heat if alternating magnetic 
field (AMF) is applied extracorporeally. For 
example: In111-SPION-chL6 for lung cancer. It 
is called thermomagnetic radiation therapy.
NEUTRON IRRADIATION
The application of neutron contributes 
to the advancement of NM. Neutron can play 
role as an analytic tool or therapeutic weapon 
against tumor.
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Neutron activation analysis (NAA).
NAA is an analytic test physically based 
upon nuclear changes.   Capture of neutron by 
atomic nucleus of the target elements in the 
sample or body creates unstable radionuclides 
which revert to a stable condition by the emission 
of ≥ 1 gamma rays of characteristic energy.  This 
energy level identifies the element and the level 
of activities indicates its abundance[11].
Neutron teletherapy.
Biologic matters contain abundant 
hydrogen of water.   As fast neutron beams 
collide elastically with tumor hydrogens, then 
protons recoil, finally stop and emit highly 
ionizing radiation to sorroundings which kills 
tumors.  This technique is suitable for skin and 
superficial tumors.   For deeper tumor locations, 
the neutron energy diminishes rapidly along its 
path to the target, because the body is a good 
shielding/moderator for neutron radiation. 
Relative biologic effectiveness (RBE) of 
neutron is closely related to its kinetic energy: 
thermal ≈ 1, epithermal ≈ 2.5, fast ≈ 5 (10-100 
keV and 2-20 MeV) or ≈ 10 (0,1-2 MeV).
Neutron Capture Therapy.
In this method, Boron (B-10) is initially 
carried to a tumor by its oncotropic vector, then 
the tumor is irradiated with thermal neutron 
beams producing Li-7 and He-4 ion of 2,3 
MeV. He-4 ion is an α particle producing dense 
ionization along its path.   RBEα = 3-8.   The 
oncotropic vector may be BSA, BPA, curcuma 
or NPs loaded with targeting agents [12].  
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